To elucidate the physiological roles during pregnancy of vascular endothelial growth factor (VEGF), we examined the temporal and spatial expression of VEGF protein and mRNA in the rat uterine and placental tissues throughout pregnancy.
The uterine tissue of nonpregnant rats, pregnant rats, and the rat placental tissue were examined by Northern blotting, in situ hybridization and immunohistochemistry.
Northern analysis revealed the existence of VEGF mRNA in the uterus and placenta regardless of the stage of estrous cycle or pregnancy. Angiogenesis is the formation of new blood vessels through the sprouting of capillaries from preexisting vessels [13] . During pregnancy, angiogenesis of the placenta and placental vascular bed in the maternal uterus is characterized by the formation of networks of neovasculatures, allowing for the steady increase in fetoplacental blood flow necessary to sustain the growing fetus [17] . Administration of an angiogenesis inhibitor to pregnant mice results in complete failure of embryonic growth due to interference with placenta formation and embryonic vascular development [18] . Although angiogenesis plays a crucial role in fetal development, the stimuli for angiogenesis in the placenta and placental bed throughout gestation are unknown.
One possible mediator for angiogenesis is vascular endothelial growth factor (VEGF), a potent mitogenic factor for vascular endothelial cells in promoting blood vessel growth [11] . VEGF, also known as vascular permeability factor, is a heparin-binding and highly conserved glycosylated dimetric protein with a molecular weight of 40-45 kDa [11] . VEGF is expressed in a variety of normal and tumor tissues including the placenta [19] , umbilical vein endothelial cells [2] , the pregnant uterus [4, 9] and trophoblasts [4] . Products of two genes, the fms-like tyrosine kinase gene (fit-1), and the kinase insert domain-containing gene (KDR/Flk-1), have been shown to be high-affinity VEGF receptors [10, 21] . The expression of the VEGF receptors was confirmed in decidual beds of mouse uterus in an early stage of pregnancy [4] . Inactivation of one or both VEGF alleles in mice resulted in markedly abnormal blood vessel formation and mid-gestational death [3, 12] . This evidence suggests the involvement of VEGF in the angiogenesis required during pregnancy. However, relatively little is known about the profile of VEGF expression in the uterus and placenta throughout pregnancy. As a part of our overall objective of elucidating the substances that sustain maternal-fetal circulation, we examined the temporal and spatial expression of VEGF protein and mRNA in the rat uterus in the nonpregnant, pregnant and puerperal periods, and in the placenta.
II.
Materials and Methods
Experimental animals
Female Wistar rats greater than 10-weeks old were obtained from Japan SLC (Shizuoka, Japan). The rats were acclimated for at least 5 days before determining the estrous cycle, and were housed in a 12-hr on/12-hr off light-dark schedule. The stages of the estrous cycle were checked by vaginal cytology according to the usual methods.
Based on these observations, each individual was assigned to a cyclic stage (diestrus, proestrus, estrus or metestrus).
Animals were monitored for 10 days before experimentation or mating, and animals not exhibiting a normal 4-to 5-day estrous cycle were excluded from the study. To obtain pregnant animals, rats were cohabited with males overnight and presence of sperm in the vagina was checked the next morning.
The day of sperm confirmation was termed day 0 of pregnancy (P0). All animal studies were conducted according to the Guidelines for Animal Experiments approved by the Animal Ethics Committee of Yamanashi Medical University.
Tissue preparation
The rats were sacrificed by cervical fracture under ether anesthesia on the day of each stage of the estrous cycle, P5, P8, P11, P15, P20 and on the 5th day in the puerperium (PP5). Animals not exhibiting pregnancy on P8, P11, P15, and P20 were excluded from the study. Three animals per each stage or gestational day were used. The uterus was immediately exposed and carefully resected. In P15 and P20 rats, the uterus was dissected, and the fetus with umbilical cord was removed from the placenta and uterus. Consequently, the uterine samples from P5 to P11 animals included all of the conceptus, and those from P15 and P20 included the placenta. Two or three uterine samples for Northern blotting and four for immunohistochemistry and in situ hybridization were obtained from each rat. The placenta and uterus of two uterine samples of the P15 and P20 animals were separated by gentle pulling and stored separately.
For Northern blotting, the samples were immediately frozen in liquid nitrogen and stored at -80°C.
For immunohistochemistry and in situ hybridization, the samples were fixed in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH 7.4) overnight at 25°C and embedded in paraffin.
Northern blotting
Total RNA was extracted from the tissues by the acid guanidinium-phenol-chloroform system (ISOGEN, NIPPON GENE, Co., Ltd., Toyama, Japan) according to the manufacturer's instructions. The isolated total RNA (20 ,ug) was fractionated by electrophoresis on a 1.5% agarose in 18% formaldehyde gel, then transferred onto a Hybond-N+ nylon membrane (Amersham) and cross-linked by ultraviolet irradiation.
After overnight prehybridization at 42°C in 50% formamide, 5 x saline sodium phosphate-ethylenediaminetetraacetic acid (SSPE), 5 x Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS), and 20pg/ml of denatured salmon sperm DNA, the membranes were hybridized overnight at 42°C with a 32P deoxycytidine triphosphate (dCTP) labeled DNA hybridization probe encoding rat VEGF. The probe was synthesized by restriction of the pU 18 vector rat VEGF cDNA clone using EcoR I and Hind III according to the method previouly reported [24] . The 500 by fragments encoding exon 1-8 were labeled with a _32P dCTP (NEN) using the BcaBEST Labeling Kit (Takara Shuzo, Co., Ltd., Shiga, Japan). After hybridization, the membranes were washed four times with 2 x SSPE, 0.1% SDS for 5 min at 25°C and with 0.2 x SSPE, 0.1 °% SDS for 15 min at 60°C. The membranes were exposed to Fuji RX film (Fuji Photo Film Co., Ltd., Tokyo, Japan) with intensifying screens for 1 to 3 days. To correct for loading and transfer differences, the membranes were stripped and reprobed with an a32P labeled probe for rat (3-actin (Wako Pure Chemical Co., Ltd., Tokyo, Japan). Total RNA from the rat lung served as a positive control according to the report of Chakraborty et al [4] . Autoradiographs were analyzed with an image analyzer (BAS 2000, Fuji Photo Film Co., Ltd.).
In situ hybridization
In situ hybridization was carried out using the nonradioactive Genius labeling and detection kit (Boehringer Mannheim GmbH, Mannheim, Germany). The rat VEGF DNA hybridization probes were prepared following the same methods used for the Northern blotting, and were labeled with digoxigenin-dUTP according to the manufacturer's instructions. 501A of Hybridization , and rat lung (Lane 8). To control for transfer efficiency and loading levels, the blots were also hybridized to a p-actin probe.
Solution I (Maxim Biotech, Inc., San Francisco, USA) containing the DNA probe was applied on each slide. Hybridization was performed overnight at 42°C in a moist chamber. Fab fragments from anti-digoxigenin-alkaline phosphatase antibody (Boehringer Mannheim) in TN solution (100 mM Tris-HC1 pH 7.5, 150 mM NaCl, 1 : 500 dilution) were used to detect the labeled DNA probes. The nuclei were counterstained with methyl green. All tissue sections were stained at the same time and sections without a DNA probe or anti-digoxigenin-alkaline phosphatase antibody were used as negative controls.
Immunohistochemistry
Paraffin-embedded tissue sections (3,um) were deparaffinized in xylene and substituted gradually in a descending ethanol series ending in water. Endogenous peroxidase activity was destroyed with 3% hydrogen peroxide (H202) for 5 min at 25°C. Sections were washed with PBS and incubated overnight at 4°C with a 1: 100 dilution of anti-rat VEGF rabbit IgG (IBL, Gumma, Japan) in 1% bovine serum albumin (BSA) in PBS. Bound primary antibody was detected using the streptavidin-biotin-peroxidase complex method (DAKO Laboratories Ltd., Kyoto, Japan). The secondary antibody was a biotinylated goat anti-rabbit immunoglobulin in 1% BSA (1 : 200 dilution) at 25°C for 20 min. Positive staining was detected by using peroxidase-conjugated streptavidin in 1% BSA (1:600 dilution) at 25°C for 20 min. Peroxidase activity was detected using a 3,3'-diaminobenzidine tetrahydrochloride (DAB: Dojindo, Kumamoto) solution containing 0.003% H2O2. The sections were lightly counterstained with hematoxylin to visualize the nuclei. Sections without primary antibody were used as negative controls.
III.
Results Fig. 1 shows the results of the Northern analysis. Specific hybridization signals were produced by the 32P-dCTP-labeled rat VEGF probe hybridized with the total RNA obtained from the pregnant-and nonpregnant rat uterus and placenta.
For P15 and P20 uterine samples, Northern analysis was performed with uterus and placenta in combination (total uterus) or separately. In all tissues studied, 20 ~Cg of total RNA was enough to yield hybridization signals that were detectable after exposure to autoradiography.
The lung tissue used as a positive control yielded a high signal. The molecular size of the hybridized messenger RNA (mRNA) species, as estimated by comparison with an RNA ladder, was found to occur between the 18S and the 285 ribosomal RNA. The results of rehybridizing the same blot to a 9-actin probe confirmed RNA integrity in this Northern analysis. The levels of VEGF mRNA in total uterus were lower than in the lung tissue, and were almost the same throughout estrus and pregnancy, as well as in the separate placenta and uterus samples on P15 and P20 (data not shown). These results were consistently confirmed in all three experiments. Results of in situ hybridization and immunohistochemistry are shown in Figs. 2 and 3. In situ hybridization for nonpregnant rat specimens showed that VEGF mRNA accumulated in myometrial smooth muscle cells, glandular epithelial cells, stromal cells (Fig. 2-A, E) , and endometrial epithelial cells during each stage of the estrous cycle. With the exception of the myometrial smooth muscle cells, the level of accumulation increased in all of the above mentioned cells upon estrus.
During pregnancy, the VEGF mRNA expression in these cells were of the same degree as that during estrus, but fetal compartments such as trophoblasts (Fig. 3-A, E) , vitelline epithelial cells and amnion were labeled more strongly. P8 and P11 sections demonstrated the highly-labeled trophoblasts invading into the endometrium (Fig. 3A) . The vitelline epithelial cells and amnion were also strongly labeled in the P15 and P20 sections. In the puerperal (PP5) uterus, VEGF mRNA was most strongly expressed in the region of mazolysis.
Through immunohistochemistry, cells stained with anti-VEGF antibody were shown to be the same as those with in situ hybridization experiments. The expression of VEGF protein was found in smooth muscle cells, stromal cells, glandular epithelial cells (Fig. 2-B, F) and epithelial cells of the endometrium in nonpregnant and pregnant uterus and trophoblasts (Fig. 3-B, F) , amnion, vitelline epithelial cells, and decidual cells (Fig. 3D) in the pregnant uterus. The highest intensity was observed in fetal compartments such as trophoblasts, vitelline epithelial cells and amnion. VEGF proteins were also detected in vascular endothelial cells, which did not express VEGF mRNA (Fig. 3-E, F) .
These results were confirmed in all of the 12 sections from the three animals, and no signals were observed in the control sections (Fig. 2-C, D) . The changes of signal intensity in the above-mentioned cells were summarized in Tables 1 and 2 . The intensity of signals in the myometrial smooth muscle cells was used as a control, since it was relatively constant regardless of the stage in the estrous cycle or pregnancy.
IV. Discussion
This study demonstrated both the consistency in spatial expression, and the variation in temporal expression of the VEGF gene and protein in uterine tissue during cyclical changes and pregnancy. This is also the first study to elucidate the profile of VEGF expression in the rat uterus and placenta throughout pregnancy.
We used a DNA probe encoding for 8 exons of VEGF mRNA in Northern analysis since the gene for both human and rat VEGF is organized into 8 exons [14, 15, 22] . The expression of the VEGF gene in the uterus and placenta were consistent with previous results using rats [9] , mice [4] Table 1 . Localization of VEGF mRNA and VEGF protein in the rat uterus during the estrous cycle. and sheep [7] . With regard to the quantitative change of VEGF mRNA during the estrous cycle or pregnancy, Chakraborty et al. [4] reported that the steady-state levels of the major VEGF mRNA transcript (4.2 kb) did not vary much during the pen-implantation period in mice, except for an increase in day-8 decidual samples. We, however, did not find any apparant quantitative difference between stages. This probably means that, since the VEGF mRNA expression occurs not only in the decidua but also in the whole uterine and placental tissues, the quantitative difference can not be detected by comparing the whole-uterine tissues.
It is also well known that Northern analysis provides only limited information for quantification of mRNA expression, and a more sensitive method such as an RNase protection assay may be required for this purpose.
To examine the cell type-specific expression of VEGF mRNA and the change throughout pregnancy, we performed in situ hybridization experiments.
Results of in situ hybridization demonstrated that spatial expression of VEGF mRNA in myometrial smooth muscle cells, glandular epithelial cells, stromal cells and endometrial epithelial cells consistently occurred during each stage of the estrous cycle. These signals increased on estrus, except in the myometrial smooth muscle cells. The spatial and temporal expression of VEGF protein as determined by immunohistochemistry was almost the same as that determined with in situ hybridization experiments except for vascular endothelial cells. These results demonstrate that the VEGF gene and protein were specifically expressed in these cells. The lack of VEGF mRNA expression in vascular endothelial cells agrees with previous studies [4, 9, 23] . It has been generally accepted that vascular endothelial cells, a main target of VEGF, do not secrete VEGF protein by themselves [1 1]. The high signals obtained on estrus and during pregnancy can be explained by estrogen regulation of VEGF expression. Estrogen induction of uterine VEGF expression has been generally accepted. Estrogen treatment induces VEGF mRNA in the ovariectomized rat uterus [9] and estradiol increases VEGF mRNA expression in the human endometrial cell line [6] . The estrogen effect may explain why the cyclic change of VEGF mRNA expression in myometrial smooth muscle cells was smaller than in other positive cells, as estrogenreceptor mRNA expression has been reported to be much lower in the human myometrium than in the endometrium [14] . It should be noted, however, that classical estrogen or progesterone response elements are not present in the promotor region of VEGF [23] , suggesting that estrogen may influence VEGF mRNA expression in an indirect fashion.
During pregnancy, the signals from cells of maternal origin were almost the same as those obtained on estrus. But the cells specifically developed during pregnancy, such as trophoblasts and vitelline epithelial cells, showed much stronger signals for VEGF mRNA.
The specific expression of VEGF in these cells subsequently resulted in the strong labeling of the labyrinth which sustains maternal-fetal circulation. The spatial expression of VEGF protein determined by immunohistochemistry was almost the same as that determined by in situ hybridization. A number of authors of histochemical and in situ 8, 19] in trophoblasts throughout pregnancy. VEGF expression by trophoblasts in early gestation is considered to play a principal role in the uterine-vessel remodeling and angiogenesis that occurs, and may influence development of the villous vasculature as well.
We also observed that trophoblasts invading into the endometrium showed a rich accumulation of VEGF mRNA and protein. Expression of VEGF at term (P20), where there is little need for new vessel growth, may signify that a critical level of VEGF is needed to maintain vessel integrity and permeability as demonstrated in other vascular beds. Furthermore, the presence of fit-1, a high-affinity VEGF receptor confirmed on trophoblasts [1, 8] , suggests that trophoblastderived VEGF could act in an autocrine manner to influence trophoblast function at all stages of gestation. The expression of VEGF in the vitelline epithelial cells and amnion might act to maintain permeability in order to sustain amniotic fluid circulation.
The VEGF expression seen in the region of mazolysis on the puerperal (PP5) uterus is considered to be involved with wound healing, which is one of the major physiological roles of VEGF.
In conclusion, the spatial expression of VEGF was relatively constant in rat maternal uterus during the estrous cycle and during pregnancy, but there was a temporal change of VEGF expression which might be induced by estrogenic regulation.
During pregnancy, VEGF, which is highly expressed in fetal tissue, especially trophoblastic and amniotic tissue, may act in a paracrine fashion to regulate maternal-fetal vascular growth and permeability changes, and to sustain fetal and placental development.
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